Evidence map›Paper›PMID 39006752›Full record

ReviewFrontiers in microbiology2024

Understanding the relationship between HCV infection and progression of kidney disease.

Meiqi Zhang, Zhongyu Han, Yumeng Lin, Zi Jin, Shuwei Zhou, Siyu Wang, Yuping Tang, Jiaxuan Li, Xueping Li, Haoran Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Meiqi Zhang *School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Zhongyu Han *School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Yumeng Lin *Naniing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China.
Zi Jin *Department of Anesthesiology and Pain Rehabilitation, Shanghai YangZhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), School of Medicine, Tongji University, Shanghai, China.
Shuwei ZhouJiangsu Key Laboratory of Molecular and Functional Imaging, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
Siyu WangDepartment of Gastroenterology, The First Hospital of Hunan University of Chinese Medicine, Changsha, China.
Yuping TangHepatobiliary Department of the Third Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, China.
Jiaxuan LiSchool of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Xueping LiSchool of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Haoran ChenDepartment of General Surgery, Chengdu Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) can cause a range of kidney diseases. HCV is the primary cause of mixed cryoglobulinaemia, which leads to cryoglobulinaemic vasculitis and cryoglobulinaemic glomerulonephritis (GN). Patients with acute cryoglobulinaemic vasculitis often exhibit acute kidney disease due to HCV infection, which typically progresses to acute kidney injury (AKI). HCV also increases the risk of chronic kidney disease (CKD) and the likelihood of developing end-stage renal disease (ESRD). Currently, direct-acting antiviral agents (DAAs) can be used to treat kidney disease at different stages. This review focuses on key findings regarding HCV and kidney disease, discusses the impact of DAAs, and highlights the need for further research and treatment.

Indexed as

acute kidney injurycryoglobulinaemiadiabetic nephropathyglomerulonephritishepatitis C viruslupus nephritisrenal cell carcinoma

Identifiers

PMID39006752
PMCPMC11239345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.